Co-amorphous (CA) formulation is a promising strategy to improve the solubility of poorly
water-soluble drugs, however, effective prediction of a CA system is a challenge. In this …

Zinc finger CCCH-type containing 15 (ZC3H15), a highly conserved protein involved in
several cellular processes, which was responsible for tumorigenesis and may be a …

Abstract Afatinib (BIBW 2992, US: Gilotrif TM, other countries: Giotrif©) is an irreversible
blocker of the ErbB family, acting at the tyrosine kinases of these proteins. In 2013, it was …

Background: There are limited comparisons of first-and second-generation EGFR tyrosine
kinase inhibitors (TKIs) in large, real-world cohorts of non-small cell lung cancer (NSCLC) …

Gefitinib is tyrosine kinase inhibitor of epidermal growth factor receptor, which exhibits
notable clinical efficacy in non-small-cell lung cancer (NSCLC) treatment. However, gefitinib …

Abstract Introduction Befotertinib (D-0316) is a novel, third-generation EGFR tyrosine kinase
inhibitor (TKI). This study evaluated befotertinib in patients with locally advanced or …

Cancer stem cells (CSCs) contribute to the cancer initiation, metastasis and drug resistance
in non-small cell lung cancer (NSCLC). Herein, we identified a miR-221/222 cluster as a …

The vast majority of our knowledge regarding cancer radiobiology and the activation of
radioresistance mechanisms emerged from studies using external beam radiation therapy …

Purpose: Imaging techniques for highly specific detection of cancer cells in vivo can have
applications ranging from preclinical drug discovery studies to clinical cancer diagnosis and …

Lung cancer has the highest mortality among cancer-related deaths worldwide. Among lung
cancers, non-small cell lung cancer (NSCLC) is the most common histological type. In the …